TegMine Therapeutics
PrivateTotal Funding Raised
$12M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
TegMine Therapeutics is a biotechnology company that develops antibody-based therapeutics targeting cancer-associated glycans and glycoproteins to improve precision oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TegMine Therapeutics Comparables
Compare TegMine Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tacalyx | 85% | |
| Combotope Therapeutics | 83% | |
| Valora Therapeutics Inc. | 83% | |
TegMine Therapeutics Funding Rounds
Historical fundraising activity
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 83% MoM.
- Nov 9, 2025
Monthly visitors grew 2342% MoM, reaching 1.4K.
TegMine Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about TegMine Therapeutics's valuation, stock price, and market status.